VIGIL NEUROSCIENCE INC. - COMMON STOCK

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference

30 янв 2025 06:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease

23 янв 2025 06:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

08 янв 2025 15:05:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Upcoming Investor Conferences

12 ноя 2024 06:00:01 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update

07 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference

05 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

17 сен 2024 06:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Cantor Global Healthcare Conference

16 сен 2024 15:05:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Upcoming September Investor Conferences

29 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update

13 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics

01 авг 2024 15:05:00 Источник Nasdaq GlobeNewswire

Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)  

30 июл 2024 15:05:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease

24 июл 2024 06:00:00 Источник Nasdaq GlobeNewswire

Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference

18 июл 2024 15:05:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

18 июл 2024 06:00:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

27 июн 2024 01:00:03 Источник Nasdaq GlobeNewswire

Vigil Neuroscience to Present in Upcoming June Investor Conferences

30 май 2024 06:05:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

08 май 2024 06:40:00 Источник Nasdaq GlobeNewswire

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

07 май 2024 15:05:01 Источник Nasdaq GlobeNewswire

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

17 апр 2024 15:05:00 Источник Nasdaq GlobeNewswire